Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Molecular Glue Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for CDK12/CRKRS drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | CDK12/CRKRS Recombinant Protein (Kinase Domain) High purity (>95%), Endotoxin controlled. Sequence Verified. Sf9 Insect Cell expressed for eukaryotic post-translational modifications. |
View CDK12 Products |
| Gene Delivery | CDK12/CRKRS Promise-ORF / Lentivirus Full-length ORF for stable cell line construction and target validation. |
View CDK12 Products |
| Benchmark Ab | Anti-CDK12/CRKRS Recombinant Antibody Sequence-verified positive control for Western Blot, IHC, and IP. |
View CDK12 Products |
| Validator | CDK12/CRKRS siRNA Set For knockdown verification and phenotype validation in DNA damage response assays. |
View CDK12 Products |
| Related Target A | CCNK (Cyclin K) Obligate binding partner of CDK12; essential for kinase activation and molecular glue-induced degradation assays. |
View CCNK Products |
| Related Target B | CDK13 Highly homologous kinase (91% identity in kinase domain) required for off-target selectivity screening. |
View CDK13 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| CDK13 Homology Off-target Screening | CDK12 and CDK13 recombinant kinase proteins strictly verified by mass spec to ensure no cross-contamination |
| Molecular Glue Ternary Complex Assembly | Co-expressed CDK12/CCNK complex available with precise stoichiometric ratios |
| Lack of Controls | Clinical-grade benchmark antibodies included for target engagement comparison |
| False Positives in Knockdown | HPLC-purified siRNA pool with chemical modifications to minimize off-target RNAi effects |
Live CDK12/CRKRS R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for CDK12/CRKRS therapeutics is intensifying, with major players shifting focus from traditional ATP-competitive small molecule inhibitors to targeted protein degraders (PROTACs) and molecular glues. As first-generation CDK12 inhibitors face limitations due to dose-limiting toxicities and selectivity issues with CDK9/CDK13, the next wave of R&D is targeting the selective degradation of the CDK12/Cyclin K complex, exploiting the "BRCAness" phenotype in homologous recombination (HR)-deficient tumors.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Molecular Glues (Cyclin K degraders) | Monte Rosa Therapeutics, Boehringer Ingelheim | Solid Tumors (mCRPC, Triple-Negative Breast Cancer) | Ternary Complex Assay (Need recombinant CDK12/CCNK co-expressed proteins) |
| Selective Small Molecule Inhibitors | AstraZeneca, Carrick Therapeutics | Ovarian Cancer, Small Cell Lung Cancer | Kinase Selectivity Assays (Need high-purity CDK12 vs CDK13/CDK9 panels) |
| PROTACs | Arvinas, Academic Spinoffs | Advanced Solid Tumors with DDR mutations | Target Ubiquitination Assays (Need sequence-verified CDK12 and E3 ligase components) |